Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism

Estrada, Gemma; Fatjó‐Vilas, Mar; Muñoz, Ma José; Pulido, Gabriel; Miñano, María José Camacho; Toledo, Edson Luiz; Illa, Josep Maria; Martín, Miguel Arrabal; Miralles, María L.; Miret, Salvador; Campanera, S.; Bernabeu, Carmelo; Navarro, M Eulalia; Fañanás, Lourdes

doi:10.1111/j.1600-0447.2010.01665.x

Cited by 78 publications

(59 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Firstly, it could be that cannabis use and the selected symptoms share a common underlying factor such as shared environmental exposure and ⁄ or genetic risk factors. (41) and suggests that age is a crucial mediator in the effect of cannabis on psychosis, which was also reflected in our results.…”

Section: Discussionsupporting

confidence: 72%

Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis

Dragt

Nieman

Schultze‐Lutter

et al. 2011

Acta Psychiatr Scand

View full text Add to dashboard Cite

on behalf of the EPOS group. Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis.Objective: Numerous studies have found a robust association between cannabis use and the onset of psychosis. Nevertheless, the relationship between cannabis use and the onset of early (or, in retrospect, prodromal) symptoms of psychosis remains unclear. The study focused on investigating the relationship between cannabis use and early and high-risk symptoms in subjects at clinical high risk for psychosis. Method: Prospective multicenter, naturalistic field study with an 18-month follow-up period in 245 help-seeking individuals clinically at high risk. The Composite International Diagnostic Interview was used to assess their cannabis use. Age at onset of high risk or certain early symptoms was assessed retrospectively with the Interview for the Retrospective Assessment of the Onset of Schizophrenia. Results: Younger age at onset of cannabis use or a cannabis use disorder was significantly related to younger age at onset of six symptoms (0.33 < r s < 0.83, 0.004 < P < 0.001). Onset of cannabis use preceded symptoms in most participants.

show abstract

Section: Discussionsupporting

confidence: 72%

Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis

Dragt

Nieman

Schultze‐Lutter

et al. 2011

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…Debido a lo discutible que resulta la diferenciación como entidades independientes de los trastornos esquizofrénicos, esquizofreniforme y esquizoafectivo, se incluyeron pacientes con estos trastornos, como parte de un espectro de una misma condición psicopatológica subyacente (29). Incluso, se ha visto que en algunos pacientes el diagnóstico inicial de esquizofrenia suele ser inestable y con frecuencia se cambia a trastorno esquizoafectivo (30).…”

unclassified

Edad de inicio de los síntomas y sexo en pacientes con trastorno del espectro esquizofrénico

Sánchez¹,

Téllez²,

Jaramillo³

2012

biomedica

View full text Add to dashboard Cite

Edad de inicio de los síntomas y sexo en pacientes con trastorno del espectro esquizofrénicoIntroducción. Existe controversia sobre la posibilidad de que la edad de inicio de la esquizofrenia y de algunas características clínicas del trastorno, sean diferentes entre hombres y mujeres. Objetivo. Evaluar la relación entre sexo, edad de inicio y síntomas negativos en pacientes con trastornos del espectro esquizofrénico. Materiales y métodos. Se evaluaron 225 pacientes para medir la edad de inicio de los síntomas y el puntaje en la escala SANS (Scale for the Assessment of Negative Symptoms). Se usaron estimadores de densidad kernel para evaluar las características de la edad de inicio. Se estimaron los parámetros de distribuciones mezcladas usando algoritmos de máxima verosimilitud. La relación síntomas negativosedad de inicio se evaluó usando regresión múltiple.Resultados. Hubo diferencia significativa en la edad de inicio según el sexo (24,5 años en hombres Vs. 27,5 años en mujeres). Se encontró asociación entre sexo y comienzo temprano de síntomas, siendo este último más frecuente en hombres. Los estimadores de densidad para la edad de inicio sugieren un modelo mezclado con tres componentes, con los siguientes parámetros: m1=21,55, sd1=5,25; m2=29,54, sd2=7,22; y m3=40,01, sd3=3,98. Al tener en cuenta el sexo, se aíslan dos estructuras bimodales: la de hombres tiene la menor media de edad de inicio (18,02 años) mientras que la de media más alta corresponde a las mujeres (41,03 años). Los coeficientes de regresión sugieren incremento en los síntomas negativos a medida que aumenta el tiempo con enfermedad. Conclusión. Nuestros resultados apoyan la hipótesis de que existe relación entre la edad de inicio de los síntomas, el sexo y las características clínicas, en pacientes con trastornos del espectro esquizofrénico, lo que demuestra que los hombres tienen un inicio más temprano y un curso de la enfermedad con mayor deterioro.Palabras clave: esquizofrenia y trastornos con características psicóticas/epidemiología, edad de inicio, distribución por edad y sexo, incidencia, prevalencia, resultado del tratamiento, modelos estadísticos. Age of onset symptoms and gender in schizophrenic spectrum disordersIntroduction. Some controversy exists concerning whether the onset of schizophrenia and some clinical characteristics of the disorder are different between males and females. Objective. The relationship between sex, age at onset and negative symptoms was evaluated in patients with schizophrenic spectrum disorders. Materials and methods. A sample of 225 patients (89 women and 136 men) were diagnosed for schizophrenia between 2008 and 2009. Each was compared for age at onset of symptoms and SANS score (Scale for the Assessment of Negative Symptoms). Kernel density estimators were used to evaluate characteristics of age of onset with respect to gender. Parameters of the mixed distributions were estimated via maximum-likelihood algorithms. Relationships between negative symptoms score and age of onset were evaluated using multi...

show abstract

“…In summary, although our data did not indicate a significant effect, there was a trend‐level signal in the same direction as some previous studies (Estrada et al., 2011) that examined rs4680, specifically that Val/Val genotype may be associated with an earlier AoP, in those who had first used cannabis relatively early in life (prior to 20 years). STATA provides the option of statistically testing for the trend of survivor functions and when we used the test for the trend of rs4680 on AoP in first cannabis users before 20 years of age, it was significant ( p = .029).…”

Section: Discussionmentioning

confidence: 99%

“…The risk genotype was Val/Val (OR 10.9, CI 2.2–54.1), with the Val/Met being associated with a lesser degree of risk (OR 2.5, CI 0.78–8.2). Consistent with this, others reported a similar gene‐environment ( COMT rs4680 – cannabis) effect on the age of onset of psychosis (AoP) among individuals within a schizophrenia spectrum disorder (Estrada et al., 2011). In individuals with schizophrenia spectrum disorders, Val/Val genotype had the earliest AoP, followed by Val/Met, followed by Met/Met.…”

Section: Introductionmentioning

confidence: 99%

Investigation of the COMT Val158Met variant association with age of onset of psychosis, adjusting for cannabis use

et al. 2017

View full text Add to dashboard Cite

Objective COMT rs4680 (Val158Met) genotype moderates the effect of cannabis on the age of onset of psychosis (AoP). We investigated the association between rs4680 and AoP, after adjusting for relevant covariates, in a Canadian Caucasian sample.MethodsOne hundred and sixty‐nine subjects with psychosis were recruited. AoP, defined as age of DSM‐IV diagnosis was established using the Structured Clinical Interview for DSM‐IV. Cannabis use data were collected using a self‐report computerized questionnaire. DNA was extracted from saliva and genotyping of the COMT Val158Met polymorphism was done by SNaPshot and TaqMan assays. Logistic regression and Kaplan–Meier analysis results are reported.ResultsIn those who had used cannabis before 20 years of age, rs4680 had a trend level effect on AoP (median AoP: Val/Val < Val/Met < Met/Met 19.37, 20.95, 21.24 years, respectively; log‐rank test p = .051).ConclusionOur data are indicative of the need to further investigate the association between the COMT rs4680 variant and AoP in the context of adolescent cannabis use.

show abstract

Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism

Abstract: Our results suggest the importance of brain maturation timing in which exposure to cannabis occurs. The COMT Val158Met genotype seems to modulate the association between cannabis and age at onset of psychotic disorders. These results are consistent with previous studies.

Cited by 78 publications

References 68 publications

Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis

Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis

Edad de inicio de los síntomas y sexo en pacientes con trastorno del espectro esquizofrénico

Investigation of the COMT Val158Met variant association with age of onset of psychosis, adjusting for cannabis use

Contact Info

Product

Resources

About